Neridronic acid for treating complex regional pain syndrome
Osteoclast inhibitors, such as neridronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
1. A method of treating changes in skin blood flow associated with complex regional pain syndrome, comprising parenterally administering neridronic acid in a salt or an acid form to a human being suffering from changes in skin blood flow associated with complex regional pain syndrome, wherein the human being has a pain intensity of at least 7 cm on the 10 cm visual analogue scale (VAS) or at least 7 on the 0-10 numerical rating scale (NRS).
2. The method of claim 1 , wherein a total of about 200 mg to about 500 mg of the neridronic acid is administered parenterally to the human being.
3. The method of claim 1 , wherein a total of about 400 mg of the neridronic acid is administered parenterally to the human being.
4. The method of claim 1 , wherein a total of about 100 mg to about 200 mg of the neridronic acid is administered parenterally to the human being within a period of about 1 month.
5. The method of claim 1 , wherein a total of about 250 mg of the neridronic acid is administered parenterally to the human being within a period of about 1 month.
6. The method of claim 2 , wherein the neridronic acid is administered in divided doses.
7. The method of claim 6 , wherein each division of the divided parenteral doses contains about 10 mg to about 150 mg of the neridronic acid.
8. The method of claim 6 , wherein each division of the divided parenteral doses contains about 62 mg to about 63 mg of the neridronic acid.
9. The method of claim 1 , wherein the complex regional pain syndrome is associated with an inciting traumatic event.
10. The method of claim 1 , wherein the human being has suffered from complex regional pain syndrome for at least 6 months.
11. The method of claim 1 , wherein the human being has suffered from complex regional pain syndrome for about 6 months to about 12 months.
12. The method of claim 1 , wherein the human being has suffered from complex regional pain syndrome for about 1 year to about 2 years.
13. The method of claim 1 , wherein the human being has an age of about 30 years to about 40 years.
14. The method of claim 1 , wherein the human being has a pain intensity of at least 8 cm on a 10 cm VAS or at least 8 on a 0-10 NRS.
15. The method of claim 1 , wherein the human being has a pain intensity of at least 9 cm on a 10 cm VAS or at least 9 on a 0-10 NRS.
16. A method of treating abnormal sudomotor activity associated with complex regional pain syndrome, comprising parenterally administering neridronic acid in a salt or an acid form to a human being suffering from abnormal sudomotor activity associated with complex regional pain syndrome, wherein the human being has a pain intensity of at least 7 cm on the 10 cm visual analogue scale (VAS) or at least 7 on the 0-10 numerical rating scale (NRS).
17. The method of claim 16 , wherein a total of about 200 mg to about 500 mg of the neridronic acid is administered parenterally to the human being.
18. The method of claim 16 , wherein a total of about 400 mg of the neridronic acid is administered parenterally to the human being.
19. The method of claim 16 , wherein a total of about 100 mg to about 200 mg of the neridronic acid is administered parenterally to the human being within a period of about 1 month.
20. The method of claim 16 , wherein a total of about 250 mg of the neridronic acid is administered parenterally to the human being within a period of about 1 month.
21. The method of claim 17 , wherein the neridronic acid is administered in divided doses.
22. The method of claim 21 , wherein each division of the divided parenteral doses contains about 10 mg to about 150 mg of the neridronic acid.
23. The method of claim 21 , wherein each division of the divided parenteral dose contains about 62 mg to about 63 mg of the neridronic acid.
24. The method of claim 16 , wherein the complex regional pain syndrome is associated with an inciting traumatic event.
25. The method of claim 16 , wherein the human being has suffered from complex regional pain syndrome for at least 6 months.
26. The method of claim 16 , wherein the human being has suffered from complex regional pain syndrome for about 6 months to about 12 months.
27. The method of claim 16 , wherein the human being has suffered from complex regional pain syndrome for about 1 year to about 2 years.
28. The method of claim 16 , wherein the human being has an age of about 30 years to about 40 years.
29. The method of claim 16 , wherein the human being has a pain intensity of at least 8 cm on a 10 cm VAS or at least 8 on a 0-10 NRS.